

## **Sirtex Medical Limited**

Results for the full year ended 30th June 2016

Gilman Wong CEO Darren Smith CFO Dr David N. Cade CMO



24th August 2016

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd




## FY 2016 overview

- Another year of strong double-digit volume, revenue and profit growth delivered
- Significant cash generation, balanced with high levels of investment for the SIR-Spheres<sup>®</sup> Y-90 resin microspheres business
- Continuation of SIRFLOX education and awareness build following publication of study data in the *Journal of Clinical Oncology*
- Completed patient recruitment in the SORAMIC and SIRveNIB major clinical studies
- Achieved regulatory clearance in Canada and new reimbursement in the Netherlands and South Africa
- $\overrightarrow{}$  Long term growth thematic remains; SIR-Spheres ~2% penetrated





## **Financial results**





## **Constant currency revenue and NPAT**

#### ✓ Summary Sales Revenue

\$232.5 million, up 32.0%(\$ 26.7 million)\$205.8 million, up 16.9%

#### **↗** Summary Net Profit After Tax


- Adjusted NPAT\*:
   Adjusted NPAT\*:
- ↗ Constant currency adjusted NPAT:

- \$53.6 million, up 32.8%
- \$56.9 million, up 40.5%
- (\$ 9.4 million)
- \$47.5 million, up 17.3%





## **FY15-FY16 reported NPAT reconciliation**








## **Dose sales and sales revenue**

Dose sales Number of units 5 Year CAGR 19.1%




#### Sales revenue

\$'000 5 Year CAGR 26.9% 232,492 APAC 176,088








Gross margin, up 50 bps – Positive impact of higher volumes & mix effects
 EBITDA margin, up 70 bps – Expenses as a % of sales declined
 NPAT margin flat – Higher amortisation (SIRFLOX), steady effective tax rate



## Net profit after tax and operating cash flow

Net profit after tax \$'000


Operating cash flow \$'000





## Earnings per share and dividend per share


Earnings per share Cents 5 Year CAGR 35.4% Dividend per share Cents 5 Year CAGR 33.8%





## **Investment in sales and marketing**

Sales and Marketing \$'000 ---% sales Geographic footprint expansion Number of sites globally ----% growth






## **Clinical and R&D investment**




Total R&D investment \* \$'000 ---% sales





## Americas

#### Americas 5 year dose sales



- **7** Dose sales of 8,420, up 19.0%
- **7** Revenue of \$185.2 million, up 35.4%
- $\overrightarrow{}$  564 treatment sites, up 14.4% on pcp
- $\neg$  Drivers of Growth:

  - Increase in referral base and users
  - Treatment expansion driven by SIRFLOX

#### 7 Outlook


- Further investment in sales & marketing
- 'Deep and Wide' strategy targeting referrers and users
- ↗ Commence supply into Canada





## Europe, Middle East & Africa (EMEA)

# **EMEA** 5 year dose sales



- **7** Dose sales of 2,528, up 11.2%
- $\overline{7}$  Revenue of \$38.9 million, up 20.0%
- $\overrightarrow{}$  306 treatment sites, up 5.2% on pcp
- $\neg$  Drivers of Growth:

  - Positive mix benefits
  - Several Middle Eastern markets

#### Outlook:


- ⊲ New market entries planned





## Asia Pacific (APAC)

#### APAC 5 year dose sales




- **7** Dose sales of 983, up 8.9%
- → 133 treatment sites, flat on pcp
- **7** Drivers of Growth:

  - Solid performance in Taiwan, Singapore and Thailand
  - ↗ Mix benefits (higher % in AU, Singapore)
- Outlook

  - Investment into AU sales and marketing






- SIRFLOX study results presented at ASCO (June 2015) and published in the Journal of Clinical Oncology (February 2016)
- Awareness of SIR-Spheres microspheres amongst Medical Oncologists who treat patients with colorectal cancer has increased markedly
  - Most highly read **JCO Original Research Article** in March 2016, second most highly read in May 2016 by the >26,000 readership base
- Indication from US market that SIR-Spheres microspheres are now considered a therapeutic option that may be integrated into earlier lines of treatment, including first-line\*
- Overall Survival (OS) data remain an important determinant of the integration of SIR-Spheres microspheres into first-line therapy



## **Progress of our lead clinical programs**



All major studies now fully recruited, SORAMIC in March, SIR veNIB in June

- Combined SIRFLOX / FOXFIRE / FOXFIRE Global studies expected to report OS data in the 1H of CY17
- Study sponsors' updated projection indicates that SARAH and SIR veNIB are expected to report data in the 1H of CY17





## Introducing the RESiN Registry


<u>R</u>adiation-<u>E</u>mitting <u>S</u>IR-Spheres <u>in</u> <u>N</u>on-resectable (**RESiN**) Liver Tumor Patient Registry<sup>1</sup>



- Multi-centre US patient registry that prospectively enrolls patients who are scheduled for treatment with SIR-Spheres Y-90 resin microspheres as part of their care plan
- Prospectively captures baseline and outcomes data across all primary and secondary (metastatic) liver cancer types, and patient populations
- Target enrollment >500 patients p.a. from 50 US academic and community hospitals
- **Vanderbilt University Medical Center primary coordinating institution**
- - Clinical data Rapidly generates real-world data outside of a narrowly defined clinical trial population
  - Reimbursement May support decisions by private payers & Medicare in rarer tumour types
  - Regulatory clearances Generates post-marketing data that may support regulatory applications
  - **Clinician awareness** Structured scientific publication strategy



## Foundation for long-term growth







## Three pillars of the 2020Vision

Maximise value of SIR-Spheres microspheres for:

- $\nearrow$  Primary and secondary liver cancer
- ✓ Kidney cancer

2 Research & Development

**SIR-Spheres** 

microspheres

SIR-SPHERES® EVOLUTION (in house & various collaborators)	CARBON CAGE TECHNOLOGY (Australian National University)	NANOPARTICLE DEVELOPMENTS (University of Sydney)	RADIOPROTECTOR PROJECT (Peter MacCallum Cancer Centre)	NEW TECHNOLOGIES
<ul> <li>New delivery apparatus</li> <li>Imaging for treatment planning</li> <li>Imageable Spheres</li> </ul>	<ul> <li>Safely deliver radioactive substances to specific cancer sites deep within the body</li> <li>Therapeutic agent for intra-peritoneal micrometastases from ovarian cancer (also with NCCS)</li> </ul>	<ul> <li>Cellular targeting to improve the effectiveness of chemotherapy</li> <li>Enhancement of external beam radiation therapy</li> </ul>	<ul> <li>Topical agent to prevent oral mucositis during radiotherapy for head &amp; neck cancer</li> <li>Oral/systemic radioprotector for military and/or civilian use</li> </ul>	<ul> <li>Continually evaluating new opportunities</li> </ul>

An R&D education event with investors/analysts is planned for late CY16

**3** Mergers & Acquisitions

Commercial ready technology that will add value and grow the business
 Seeking to capitalise on our capabilities and infrastructure





## Outlook – FY17

- Double digit dose sales growth to continue in FY17 large, underpenetrated market remains (~2% to date)
- Continued strong investment into sales and marketing, clinical and medical required to build awareness and drive adoption; supports long-term growth
- ✓ 'Lunch and Learn' event early CY17 prior to expected clinical results
- Preparations well advanced in anticipation of SARAH, SIRveNIB and SIRFLOX / FOXFIRE / FOXFIRE Global results in first half of CY17
- $\overrightarrow{}$  R&D education event planned for late 2016
- 2020Vision continues to drive our planning and execution strategies across the globe



# Thank you

